drugset / Trial / NCT05847218
Phase 1 Clinical Trial of RHN-001 in Healthy Adult Volunteers
Phase 1
Completed
64 enrolled
RH Nanopharmaceuticals
Center for Bioequivalence Studies and Clinical Research · collab
RandomizedCrossoverTriple-blindOther
Summary
The goal of this clinical Trial is to assess the safety, tolerability and Pharmacokinetic profile of 750 mg single oral dose of RHN-001 and 1500 mg of RHN-001 administered orally in fasted and fed conditions in healthy adult volunteers.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2023-03-19
- Completion
- 2023-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RHN-001 | Unknown | 750 mg | Oral |
| Subject | RHN-001 | Unknown | 1500 mg | Oral |
Indications
No indication recorded.